Navigation Links
INVO Bioscience Announces Planned Submission To ANVISA For Brazilian Approval Following Completion of Clinical Trial

BEVERLY, Mass., June 14, 2011 /PRNewswire/ -- INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced the completion of a 40 patient clinical trial conducted in Rio de Janeiro, Brazil. Results from this completed clinical study will be submitted to the National Health Surveillance Agency (ANVISA) for the purpose of gaining registration and approval for the sale of the INVOcell device in Brazil. As originally announced on January 25, 2011, the trial was designed as a 40 patient clinical trial to establish safety, efficacy and comparative in-vitro fertilization (IVF) measures of the INVOcell device.

This trial was sponsored and conducted by Dr. Francisco Augusto Colucci Coelho of the Center of Infertility and Fetal Medicine of North Rio de Janeiro, Brazil. Upon computation of the results of Dr. Coelho's Brazilian clinical trial, along with the recently announced clinical trial results from Dr. Elkin Lucena of the Colombian Fertility and Sterility Center (CECOLFES) in Colombia, South America, data will be submitted to ANVISA for registration and approval in the coming weeks.

"We are very excited that Dr. Coelho has completed this 40 patient clinical trial in Brazil," stated Kathleen Karloff, chief executive officer for INVO Bioscience. "While the results are currently being computed and finalized, we are optimistic that the data submitted by Dr. Coelho, in conjunction with the results from Dr. Lucena's clinical trial in Colombia, represent an important step forward in opening the doors to the enormous Brazilian marketplace for INVOcell.  We are grateful for the efforts of Dr. Coelho and his team in undertaking this effort to obtain approval, which could offer the more than 15 million infertile couples in Brazil an effective and cost efficient option while eliminating the many risks of multiple births."

Dr. Francisco Augusto Colucci Coelho, commented, "Initial indications point to strong comparative results between INVOcell and traditional in-vitro fertilization measures without any safety concerns.  We look forward to finalizing the submission of this application to ANVISA with the goal of obtaining registration and approval for the sale the INVOcell device.  As I originally stated, the treatment of couples with INVOcell is making the original purpose of the Human Reproductive Service of the Hospital School possible again by allowing universal access for infertile couples at a very reasonable cost. I remain excited to be at the leading edge in advancing the development of this breakthrough in reproductive medicine for the people of Brazil."

In Brazil, there are more than 125 fertility centers licensed to perform assisted reproductive procedures.  According to the Brazilian Ministry of Health there are more than 15 million infertile couples in Brazil, with less than 1% of these couples actively seeking treatment. The many advantages of the INVOcell device and procedure include:

  • the processing of significantly fewer eggs from patients, reducing the occurrence of multiple pregnancies and the attendant costs and complications;
  • the relative cost advantages of the INVOcell procedure compared to traditional IVF treatments;
  • pregnancy rates that are comparable to traditional IVF treatments.

  • INVOcell is CE Mark approved in Europe and Canada and conforms with all consumer health and safety requirements. INVOcell is currently marketed and sold in Austria, Bolivia, Cameroon, Columbia, the Dominican Republic, Guatemala, Nicaragua, Pakistan, Panama, Peru, Spain, Togo, Turkey, Poland, Spain, Switzerland, Greece, and Bulgaria. The company continues to market its products in all applicable countries covered by CE Mark or other local accepted criteria.  Additionally, the company has commenced registration processes in Ukraine, China, Argentina, Venezuela, Russia and now Brazil, while continuing to explore additional appropriate countries to begin the registration process to market its products.

    About INVO Bioscience

    INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit

    About The Center of Infertility and Fetal Medicine of North Rio de Janeiro

    The Center for Fetal Medicine and Infertility is associated with the Hospital of the Medicine College of Campos in the state of Rio de Janeiro in partnership with local government offering services to couples for the public health system. The Infertility Center was the first laboratory to obtain certification from ANVISA as well as offered the first agreement for public assistance (free) in the state of Rio de Janeiro.

    Private Securities Litigation Reform Act of 1995

    This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.Contact:Kathleen KarloffINVO Bioscience, Inc.978-878-9505 ext

    SOURCE INVO Bioscience, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time
    2. Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service
    3. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines
    4. Ardea Biosciences to Present at Upcoming Investor Conferences
    5. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Receives the Virginia Bioscience Company of the Year Award
    6. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
    7. Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum
    8. TEI Biosciences Wins SBANE 2011 New England Innovation Award
    9. Transposagens piggyBac™ Vectors to be Distributed by System Biosciences
    10. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
    11. Cell Biosciences Announces Issuance of Three US Patents
    Post Your Comments:
    (Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
    (Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
    (Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
    (Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
    Breaking Biology Technology:
    (Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
    (Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
    (Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
    Breaking Biology News(10 mins):